Article Sidebar
DOI:
10.4314/tjpr.v14i2.5Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Formulation and In vitro Dissolution Characteristics of Sustained-Release Matrix Tablets of Tizanidine Hydrochloride
Abstract
Purpose: To formulate sustained-release (SR) matrix tablets of tizanidine hydrochloride (THC) and to investigate the effect of matrix polymer type on drug release profile of drug.
Methods: Matrix tablets of THC were prepared by direct compression method using a combination of hydroxypropylmethylcellulose (HPMC) and ethylcellulose (EC) in varying ratios. In all the formulations, the amount of THC was 6.87 mg (equivalent to 6 mg base). USP type-I (basket) apparatus was used for the dissolution study. The dissolution study was performed in 0.1M HCl for the first 2 h and in phosphate buffer (pH 6.8) for another 10 h. The dissolution data were subjected to drug release models to ascertain the kinetics of drug release. Additionally, in vitro swelling and buoyancy studies were carried out on the optimized formulation. The optimized formulation was compared with a commercial reference product using similarity factor (ƒ2) test.
Results: F4 formulation, containing 145 g of HPMC only, (with ƒ2 value of 67.38) was selected as optimized formulation (compared to the reference commercial product), and it released 97.84 % of the drug in 12 h. The release data showed best fit to first-order kinetics (R2 = 0.9963 - 0.9989), though nonsignificantly (p > 0.05) different from the Higuchi model (R2 = 0.9813 - 0.9955) except for formulation F6. Based on Koppcha model data, drug release mechanism involved both diffusion and erosion (n = 0.513 - 0.597) with diffusion being dominant. The optimized formulation exhibited 162 % swelling at the end of 11 h, after which no further weight gain occurred.
Conclusion: Suitable sustained-release tablets of tizanidine hydrochloride have been successfully prepared using direct compression Drug release is sustained by increasing the content of the matrix polymers used.
Keywords: Tizanidine, HPMC, EC, Koppcha, Hixson-Crowell, Stokes-Einstein’s equation
